Endo International PLC at JPMorgan Global High Yield & Leveraged Finance Conference (Virtual) Transcript
Good morning, again, everybody. I'm David Common, and I cover all of health care for the non-investment-grade space at JPMorgan. We're kicking off today with Endo Pharmaceuticals. We're very happy to have Mark Bradley and Laure Park. And I want to remind you that we do have this ask a question feature, which I think most investors are familiar with.
So again, don't be shy. But I actually have about a dozen questions. We're not going to go through slides. I'm just going to launch into them. And hopefully, I will sort of preempt many of the things that are on your mind. (Operator Instructions) So Mark, I guess, where I'd like to start to sort of level set people because, as you know, we're not as expert as really your typical equity investors, I would say.
Can we just review that BioSpecifics acquisition? Tell us how long you were thinking about doing that deal? Why it came together last year? And then the strategic and financial implications for you.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
